Current Topics in the Treatment of Prostate Cancer with Low-Dose-Rate Brachytherapy

Urologic Clinics of North America

Volumn 37, Issue 1, 2010, Pages 83-96

  Stock, Richard G ^a   Stone, Nelson N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Prostate cancer; Treatment; Ultrasound

Indexed keywords

ANTIANDROGEN;

BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSIMETRY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LONG TERM CARE; MORBIDITY; MULTIMODALITY CANCER THERAPY; NOCTURIA; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RECTUM FISTULA; RECTUM INJURY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION;

BRACHYTHERAPY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RISK FACTORS; TREATMENT OUTCOME;

EID: 75249096607     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2009.11.013     Document Type: Review

References (91)

1. Holm H.H., and Gammelgaard J. Ultrasonically guided precise needle placement in the prostate and seminal vesicles. J Urol 18 3 (1981) 385-387
2. Torp-Pedersen S., Holm H.H., and Littrup P.J. Transperineal I-125 seed implantation in prostate cancer guided by transrectal ultrasound. Prog Clin Biol Res 237 (1987) 143-152
3. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32 1 (1995) 219-225
4. Anderson L.L. Spacing nomographs for interstitial implants of I-125 seeds. Med Phys 3 (1976) 48
5. Stock R.G., Stone N.N., Lo Y.C., et al. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 48 3 (2000) 899-906
6. Bice Jr. W.S., Prestidge B.R., Grimm P.D., et al. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 41 4 (1998) 921-927
7. Stone N.N., Hong S., Lo Y.C., et al. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. Brachytherapy 2 (2003) 17-25
8. Rivardl M.J., Butler W.M., Devlin P.M., et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy 6 (2007) 34-37
9. Stock R.G., and Stone N.N. Importance of post implant dosimetry in permanent prostate brachytherapy. Eur Urol 41 (2002) 434-439
10. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following I-125 prostate brachytherapy using a rectal dose volume histogram analysis. Int J Radiat Oncol Biol Phys 50 (2001) 335-341
11. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
12. Potters L., Huang D., Calugaru E., et al. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology 62 (2003) 1073-1077
13. Papagikos M.A., deGuzman A.F., Rossi P.J., et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V100 superior to D90?. Brachytherapy 4 (2005) 252-258
14. Morris W.J., Keyes M., Palma D., et al. Evaluation of dosimetric paramenters and disease response after 125iodine transperineal brachytherapy for low- and intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 73 5 (2009) 1432-1438
15. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
16. Miles E.F., Nelson J.W., Alkaissi A.K., et al. Equivalent uniform dose, D90, and V100 correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer. Brachytherapy 7 (2008) 206-211
17. Kao J., Stone N.N., Lavaf A., et al. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys 70 (2008) 96-101
18. Stock R.G., Stone N.N., Cesaretti J., et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and post-treatment biopsies. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
19. Taira A.V., Merrick G.S., Galbreath R.W., et al. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys (2009) [Epub ahead of print]
20. Stone NN, Stock RG, Cesaretti JA, et al. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys. [Epub ahead of print].
21. Makarov D.V., Trock B.J., Humphreys E.B., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007) 1095
22. Rodrigues - Covarrubias F., Larre S., De La Taille A., et al. The outcome of patients with pathological Gleason score ≥ 8 prostate cancer after radical prostatectomy. BJU Int 101 (2008) 305
23. Lau W.K., Bergstralh E.J., Blute M.L., et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 167 (2002) 117
24. Donohue J.F., Bianco F.J., Kuroiwa K., et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 176 (2006) 991
25. Desireddi N.V., Roehl K.A., Loeb S., et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 70 (2007) 950
26. Swanson G.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225
27. Hu J.C., Wang Q., Pashos C.L., et al. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol 26 (2008) 2278
28. Lee A.K. Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol 16 (2006) 20
29. Pilepich M.V., Winter K., John M., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
30. Pilpich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
31. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360 (2002) 103-108
32. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008) 289-295
33. Horwitz E.M., Bae K., Hanks G.E., et al. Ten- year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (2008) 2497-2504
34. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen deprivation therapy does not impact cause specific survival or overall survival in high risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 68 (2007) 34
35. D'Amico A.V., Moran B.J., Braccioforte M.H., et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 27 24 (2009) 3923-3928
36. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
37. Zeitman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose versus high dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239
38. Stock RG, Cesaretti JA, Hall S, et al. Outcomes for patients with high grade prostate cancer treated with a combination of brachytherapy, external beam irradiation and hormonal therapy. BJU. [Epub ahead of print].
39. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
40. Stock R.G., Cesaretti J.A., Unger P., et al. Distant and local recurrence in patients with biochemical failure after prostate brachytherapy. Brachytherapy 7 3 (2008) 217-222
41. Stock R.G., Cesaretti J.A., and Stone N.N. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 64 3 (2006) 810-816
42. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 179 Suppl 5 (2008) S20-S24
43. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67 1 (2007) 57-64
44. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110 3 (2007) 551-555
45. Blasko J.C., Ragde H., and Grimm P.D. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl 137 (1991) 113-118
46. Vijverberg P.L., Blank L.E., Dabhoiwala N.F., et al. Analysis of biopsy findings and implant quality following ultrasonically-guided 125I implantation for localised prostatic carcinoma. Br J Urol 72 (1993) 470-477
47. Wallner K., Roy J., and Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 14 (1996) 449-453
48. Storey M.R., Landgren R.C., Cottone J.L., et al. Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. Int J Radiat Oncol Biol Phys 43 (1999) 565
49. Mabjeesh N.J., Chen J., Stenger A., et al. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. Urology 70 (2007) 548-553
50. Elshaikh M.A., Angermeier K., Ulchaker J.C., et al. Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology 61 (2003) 152-155
51. Terk M.D., Stock R.G., and Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 160 (1998) 1379
52. 125Iodine implantation for localized prostate cancer using percutaneous approach. J Urol 153 (1995) 1020-1025
53. Dattoli M., Wallner K., Sorace R., et al. Pd-103 brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 35 (1996) 1-5
54. Ragde H., and Korb L. Brachytherapy for clinically localized prostate cancer. Semin Surg Oncol 18 (2000) 45-51
55. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47 (2000) 121
56. Benoit R.M., Naslund M., and Cohen J.L. Complications after prostate brachytherapy in the Medicare population. Urology 55 (2000) 91-96
57. Zeitlin S.I., Sherman J., Raboy A., et al. High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 160 (1998) 91
58. Stone NN, Marshall DT, Stone JJ, et al. Does neoadjuvant hormonal therapy improve urinary function when given to men with very large prostates undergoing prostate brachytherapy? J Urol. [Epub ahead of print].
59. 125I prostate implantation. Int J Radiat Oncol Biol Phys 28 (1994) 985
60. Desai J., Stock R.G., Stone N.N., et al. Acute morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 6 (1998) 135-141
61. Tanaka N., Fujimoto K., Hirao Y., et al. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after 125I permanent. brachytherapy for localized prostate cancer. Urology 74 (2009) 407-413
62. Keyes M., Miller S., Moravan V., et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 73 4 (2009) 1023-1032
63. Matzkin H., Kaver I., Stenger A., et al. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning. Urology 62 (2003) 497-502
64. Niehaus A., Merrick G.S., Butler W.M., et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 64 1 (2006) 136-143
65. Stone N.N., and Stock R.G. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. J Urol 177 (2007) 925-928
66. Nag S., Pak V., Blasko J., et al. Brachytherapy for prostate cancer. Principles and practice of brachytherapy (1997), Futura Publ, Armonk (NY) p. 421-40
67. Gelblum D.A., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45 (1999) 59
68. Bittner N., Merrick G.S., Wallner K.E., et al. The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy. Brachytherapy 6 (2007) 258-266
69. Blasko J.C., Wallner K., Grimm P.D., et al. PSA based disease control following ultrasound guided I-125 implantation for stage T1/T2 prostatic carcinoma. J Urol 154 (1995) 1096-1099
70. Beyer D.C., and Priestley J.B. Biochemical disease-free survival following I125 prostate implantation. Int J Radiat Oncol Biol Phys 37 (1997) 559-563
71. Wallner K., Lee H., Wasserman S., et al. Low risk of urinary incontinence following prostate brachytherapy in patients with prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 37 (1997) 565-569
72. Stone N.N., and Stock R.G. Prostate brachytherapy: treatment strategies. J Urol 162 (1999) 421
73. Talcott J.A., Clark J.C., Stark P., et al. Long-term treatment-related complications of brachytherapy for early prostate cancer: a survey of treated patients. Proc Annu Meet Am Soc Clin Oncol 18 (1999) 1196a
74. Nag S., Scaperoth D.D., Badalament R., et al. Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. Urology 45 (1995) 87-92
75. Stone N.N., and Stock R.G. Long-term urinary, sexual and rectal morbidity treated with I-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 69 (2007) 339-342
76. Anderson J.F., Swanson D.A., Levy L.B., et al. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology 74 (2009) 601-605
77. Kollmeier M.A., Stock R.G., Cesaretti J., et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 157 (2005) 808-812
78. Critz F.A., Tarlton R.S., and Holladay D.A. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer: I-125 implant followed by external-beam radiation. Cancer 75 (1995) 2383
79. Stone N.N., Ratnow E.R., and Stock R.G. Prior transurethral resection does not increase morbidity following real-time ultrasound guided prostate seed implantation. Tech Urol 6 (2000) 123-127
80. Grado G.L., Larson T.R., Balch C.S., et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 42 (1998) 289-298
81. Hu K., and Wallner K. Clinical course of rectal bleeding following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 41 (1998) 263-265
82. Gelbum D.Y., and Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 48 (2000) 119-124
83. Theodorescu D., Gillenwater J.Y., and Koutrouvelis P.G. Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 89 10 (2000) 2085-2091
84. Sarosdy M.F. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer 101 (2004) 754-760
85. Stone NN, Cesaretti JA, Rosenstein B. et al. Do high radiation doses in locally advanced prostate cancer patients treated with Pd-103 implant plus external beam irradiation cause increased urinary, rectal and sexual morbidity? Brachytherapy. [Epub ahead of print].
86. Stock R.G., Kao J., and Stone N.N. Penile erection function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 165 (2001) 436-439
87. Taira A.V., Merrick G.S., Galbreath R.W., et al. Erectile function durability following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 75 3 (2009) 639-648
88. Critz F.A., and Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 172 6 Pt 1 (2004) 2232-2238
89. Stock R.G., Ho A., Cesaretti J.A., et al. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66 2 (2006) 389-394
90. Stone N.N., Potters L., Davis B.J., et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate. Int J Radiat Oncol Biol Phys 73 2 (2009) 341-346
91. Lee W.R., McQuellon R.P., Harris-Henderson K., et al. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 46 (2000) 27